Stock & Company Details
CRISPR Therapeutics AG $CRSP
Price:
N/A
N/A
97M
$5.2B
52 Week High:
N/A
10 Day Average Volume:
N/A
-8.74
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
CRSP technical indicators
Latest CRISPR Therapeutics AG (CRSP) indicator readings as of 2026-10-29.
CRSP's 14-day RSI is 56.0, in neutral territory. ADX reads 13.3, indicating a range-bound market rather than a trend. MACD (12, 26, 9) is -0.60, below the zero line.
CRSP backtested strategy results
How 4 rule-based strategies performed on CRISPR Therapeutics AG (CRSP) over recent history, last backtested 2026-10-30. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +35.7% | 29% | 14 | -49.6% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -31.1% | 26% | 31 | -62.8% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -59.7% | 24% | 29 | -69.8% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +57.1% | 57% | 21 | -28.4% |
Overview
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Finance Bot
Ask your questions
Start by typing a question below.
